-
Je něco špatně v tomto záznamu ?
In situ formed aldehyde-modified hyaluronic acid hydrogel with polyelectrolyte complexes of aldehyde-modified chondroitin sulfate and gelatin: An approach for minocycline delivery
T. Habibah, J. Matonohová, J. Kulhánek, U. Fitzgerald, M. Ingr, M. Pravda, A. Pandit, V. Velebný
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- aldehydy chemie MeSH
- chondroitinsulfáty * chemie MeSH
- hydrogely * chemie farmakologie MeSH
- interleukin-6 metabolismus MeSH
- kyselina hyaluronová * chemie MeSH
- lékové transportní systémy metody MeSH
- lidé MeSH
- minocyklin * chemie farmakologie aplikace a dávkování MeSH
- nosiče léků * chemie MeSH
- polyelektrolyty * chemie MeSH
- uvolňování léčiv MeSH
- želatina * chemie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Polysaccharides like hyaluronan (HA) and chondroitin sulfate (CS) are native of the brain's extracellular matrix crucial for myelination and brain maturation. Despite extensive research on HA and CS as drug delivery systems (DDS), their high water solubility limits their application as drug carriers. This study introduces an injectable DDS using aldehyde-modified hyaluronic acid (HAOX) hydrogel containing polyelectrolyte complexes (PEC) formed with calcium, gelatin, and either CS or aldehyde-modified CS (CSOX) to deliver minocycline for Multiple Sclerosis therapy. PECs with CSOX enable covalent crosslinking to HAOX, creating immobilized PECs (HAOX_PECOX), while those with CS remain unbound (HAOX_PECS). The in situ forming DDS can be administered via a 20 G needle, with rapid gelation preventing premature leakage. The system integrates into an implanted device for minocycline release through either Fickian or anomalous diffusion, depending on PEC immobilization. HAOX_PECOX reduced burst release by 88 %, with a duration of 127 h for 50 % release. The DDS exhibited an elastic modulus of 3800 Pa and a low swelling ratio (0-1 %), enabling precise control of minocycline release kinetics. Released minocycline reduced IL-6 secretion in the Whole Blood Monocytes Activation Test, suggesting that DDS formation may not alter the biological activity of the loaded drug.
Contipro a s Dolní Dobrouč 401 Dolní Dobrouč 56102 Czechia
Faculty of Technology Tomas Bata University in Zlin Vavrečkova 5669 Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018672
- 003
- CZ-PrNML
- 005
- 20241024111300.0
- 007
- ta
- 008
- 241015e20240702enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.carbpol.2024.122455 $2 doi
- 035 __
- $a (PubMed)39174092
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Habibah, Tutut $u Contipro a.s. Dolní Dobrouč 401, Dolní Dobrouč, 56102, Czechia; Faculty of Technology, Tomas Bata University in Zlin, Vavrečkova, 5669, Czechia
- 245 10
- $a In situ formed aldehyde-modified hyaluronic acid hydrogel with polyelectrolyte complexes of aldehyde-modified chondroitin sulfate and gelatin: An approach for minocycline delivery / $c T. Habibah, J. Matonohová, J. Kulhánek, U. Fitzgerald, M. Ingr, M. Pravda, A. Pandit, V. Velebný
- 520 9_
- $a Polysaccharides like hyaluronan (HA) and chondroitin sulfate (CS) are native of the brain's extracellular matrix crucial for myelination and brain maturation. Despite extensive research on HA and CS as drug delivery systems (DDS), their high water solubility limits their application as drug carriers. This study introduces an injectable DDS using aldehyde-modified hyaluronic acid (HAOX) hydrogel containing polyelectrolyte complexes (PEC) formed with calcium, gelatin, and either CS or aldehyde-modified CS (CSOX) to deliver minocycline for Multiple Sclerosis therapy. PECs with CSOX enable covalent crosslinking to HAOX, creating immobilized PECs (HAOX_PECOX), while those with CS remain unbound (HAOX_PECS). The in situ forming DDS can be administered via a 20 G needle, with rapid gelation preventing premature leakage. The system integrates into an implanted device for minocycline release through either Fickian or anomalous diffusion, depending on PEC immobilization. HAOX_PECOX reduced burst release by 88 %, with a duration of 127 h for 50 % release. The DDS exhibited an elastic modulus of 3800 Pa and a low swelling ratio (0-1 %), enabling precise control of minocycline release kinetics. Released minocycline reduced IL-6 secretion in the Whole Blood Monocytes Activation Test, suggesting that DDS formation may not alter the biological activity of the loaded drug.
- 650 12
- $a kyselina hyaluronová $x chemie $7 D006820
- 650 12
- $a želatina $x chemie $7 D005780
- 650 12
- $a chondroitinsulfáty $x chemie $7 D002809
- 650 12
- $a hydrogely $x chemie $x farmakologie $7 D020100
- 650 12
- $a minocyklin $x chemie $x farmakologie $x aplikace a dávkování $7 D008911
- 650 12
- $a polyelektrolyty $x chemie $7 D000071228
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a aldehydy $x chemie $7 D000447
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lékové transportní systémy $x metody $7 D016503
- 650 _2
- $a interleukin-6 $x metabolismus $7 D015850
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Matonohová, Jana $u Contipro a.s. Dolní Dobrouč 401, Dolní Dobrouč, 56102, Czechia
- 700 1_
- $a Kulhánek, Jaromír $u Contipro a.s. Dolní Dobrouč 401, Dolní Dobrouč, 56102, Czechia
- 700 1_
- $a Fitzgerald, Una $u CURAM, SFI Centre for Research on Biomedical Devices, Biomedical Engineering, University of Galway, Upper Newcastle, H91 W2TY, Ireland
- 700 1_
- $a Ingr, Marek $u Faculty of Technology, Tomas Bata University in Zlin, Vavrečkova, 5669, Czechia
- 700 1_
- $a Pravda, Martin $u Contipro a.s. Dolní Dobrouč 401, Dolní Dobrouč, 56102, Czechia. Electronic address: Martin.pravda@contipro.com
- 700 1_
- $a Pandit, Abhay $u CURAM, SFI Centre for Research on Biomedical Devices, Biomedical Engineering, University of Galway, Upper Newcastle, H91 W2TY, Ireland
- 700 1_
- $a Velebný, Vladimír $u Contipro a.s. Dolní Dobrouč 401, Dolní Dobrouč, 56102, Czechia
- 773 0_
- $w MED00006149 $t Carbohydrate polymers $x 1879-1344 $g Roč. 343 (20240702), s. 122455
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39174092 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111254 $b ABA008
- 999 __
- $a ok $b bmc $g 2201517 $s 1230645
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 343 $c - $d 122455 $e 20240702 $i 1879-1344 $m Carbohydrate polymers $n Carbohydr Polym $x MED00006149
- LZP __
- $a Pubmed-20241015